Metrics and Acquisition Modes for Fixation Stability as a Visual Function Biomarker

Etienne M. Schönbach,1 Mohamed A. Ibrahim,1 Xiangrong Kong,1,2 Rupert W. Strauss,1,3–6 Beatriz Muñoz,1 David G. Birch,7 Janet S. Sunness,8 Sheila K. West,1 and Hendrik P. N. Scholl1,6

1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2Department of Biostatistics and Epidemiology, University of Massachusetts-Amherst, Amherst, Massachusetts, United States
3Moorfields Eye Hospital, London, United Kingdom
4Department of Ophthalmology, Johannes Kepler University, Linz, Austria
5Department of Ophthalmology, Medical University, Graz, Austria
6Department of Ophthalmology, University of Basel, Basel, Switzerland
7Retina Foundation of the Southwest, Dallas, Texas, United States
8Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, Baltimore, Maryland, United States

Correspondence: Hendrik P. N. Scholl, Department of Ophthalmology, University of Basel, Universitätsspital Basel, Mittlere Strasse 91, CH-4031 Basel, Switzerland; Hendrik.Scholl@usb.ch.

Submitted: February 18, 2017
Accepted: July 5, 2017

Citation: Schönbach EM, Ibrahim MA, Kong X, et al. Metrics and acquisition modes for fixation stability as a visual function biomarker. Invest Ophthalmol Vis Sci. 2017;58:BIO268–BIO276. DOI:10.1167/iovs.17-21710

PURPOSE. To compare different metrics and acquisition modes of fixation stability as a new visual function biomarker in a large cohort of patients with ABCA4-related Stargardt disease from the multicenter prospective ProgStar study.

METHODS. Fixation was tested during a separate fixation exam and also dynamically during a sensitivity exam, using fundus-tracking microperimetry (Nidek MP-1). Fixation data were analyzed using the bivariate contour ellipse area (BCEA), the 2/4 degree method, and the Fujii classification.

RESULTS. In a total of 235 patients, the mean BCEA was larger when measured during the sensitivity exam (418 eyes; 12.5 vs. 4.6 deg² during the fixation task in 427 eyes). Correlations between the two tests were generally weak. Fixation stability during the sensitivity test was significantly correlated with visual acuity. Comparing the BCEA values and the corresponding Fujii categories for these eyes revealed ranges of overlap where an eye with one defined BCEA value can fall into each of the three Fujii categories.

CONCLUSIONS. Patients may have limited ability to fixate over defined time periods, which leads to significant differences between shorter and longer measurements of fixation stability. The most appropriate way to use this functional biomarker appears to be using continuous metrics for fixation stability, such as the BCEA, during a macular sensitivity test.

Keywords: fixation, Fujii method, fundus-tracking microperimetry, BCEA, Stargardt

The commonest type of juvenile macular degeneration is autosomal recessive Stargardt disease (STGD1) with an estimated prevalence of 1/8000 to 1/10,000.1 Although foveal-sparing cases with preserved visual acuity have been described,2–4 most cases show central involvement.5,6 As a result, bilaterally symmetrical loss of visual acuity down to 20/200 or 20/400 is typically observed in STGD1.7,8 However, recent evidence suggests that visual acuity is not a sensitive biomarker for longitudinal change of visual function.8

In healthy observers, eye movements such as microsaccades and tremor keep the retina constantly in motion.9 The magnitude of these movements, however, is very small.9 Eyes with various forms of central macular disease show eccentric and unstable fixation with bivariate contour ellipse areas (BCEA) approximately 10 times as large as in normal eyes.10 Fixation stability is a functional biomarker introduced to more comprehensively assess the function of the macula.11 It positively correlates with reading speed,12–15 visual acuity,14,16–18 and visual search ability19 in patients with macular disease. Fixation stability testing using different devices has been shown to yield similar results in normal eyes and eyes with macular disease.20 It has been shown that the improvement in fixation stability is predictive of the visual outcome in patients with macular hole surgery.21

Given the emerging therapeutic approaches for retinal diseases,22,23 there is a need to identify the most appropriate outcome parameters and visual function biomarkers for clinical trials.24–27 This report compares different metrics and different modes of acquisition to report fixation values in a large cohort of patients with genetically confirmed STGD1. It tests the hypothesis that there is a strong correlation between the different metrics of fixation stability and that they are interchangeable. Furthermore, it tests the hypothesis that the fixation results obtained during a separate fixation exam11 and those obtained during a macular sensitivity26 test are interchangeable.

METHODS

The ProgStar Study

In this study, research is based on the baseline data collected as part of the multicenter prospective ProgStar study, which is registered at www.clinicaltrials.gov (Identifier NCT019777846). The Guidelines of Good Clinical Practice of the International...
Fixation Stability in Stargardt Disease

Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, the applicable regulatory requirements, and the current Declaration of Helsinki were followed. The study is in compliance with the Health Insurance Portability and Accountability Act. Prior to enrollment of the first patient, the Western Institutional Review Board, the local institutional review boards (IRB), and the Human Research Protection Office of the U.S. Army Medical Research & Materiel Command granted ethics committee approval. Written informed consent was obtained from all subjects after explanation of the nature and possible consequences of the study.

Inclusion Criteria

ProgStar Report No. 1 describes in detail the design, organization, baseline characteristics, and inclusion and exclusion criteria.28 The inclusion criteria were set along the needs of a natural history study that investigates novel biomarkers for retinal degenerative diseases; the following needs of a natural history study that investigates novel biomarkers for retinal degenerative diseases; the following criteria were critical for the presented subproject: Patients (aged ≥6 years) with ≥2 ABCA4 mutations or 1 ABCA4 mutation plus a phenotype typical of STGD1 were enrolled if fundus autofluorescence testing revealed ≥1 well-demarcated area of atrophy with a minimum diameter of 300 μm but a total lesion area ≤12 mm². Best-corrected visual acuity (BCVA) had to be ≥20 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/400 Snellen equivalent). Clear ocular media and patient ability to perform all examinations were required.

Procedure

Microperimetric macular sensitivity and fixation exams were performed with the Nidek MP-1 microperimeter (Navis Software 1.7.0 or higher; Nidek Technologies Srl, Albignasego, PD, Italy) at eight out of nine participating sites, and only exams performed with the Nidek MP-1 were included. Real-time retinal imaging is rendered possible through an infrared fundus camera with an included liquid crystal display to display a single red cross (2° visual angle in extension and 1° visual angle in thickness as default, both increasable if necessary) on a white, monochromatic background.

Fixation stability was assessed during two tasks (Fig. 1). For the fixation module, patients are asked to monocularly fixate a target during a short independent fixation exam. Alternatively, fixation results were also obtained during microperimetric macular sensitivity testing (dynamic testing). In both cases, the patient’s retina is being tracked and a cloud of fixation points is thus generated. The Fujii method uses a circle of 2° and 4°, separated by a standard deviation of 2° (2/4 degree method) and the Fujii category determined.29 “Stable” meant that at least 75% of all fixation points were within the 2° circle. “Relatively unstable” meant that less than 75% of all fixation points were within the 2° circle but at least 75% were within the 4° circle. “Unstable” meant that less than 75% of all fixation points were within the 4° circle. Additionally, the global BCEA for one, two, and three standard deviations was calculated using the following equation:

$$BCEA = 2k \pi \sigma_h \sigma_v \left(1 - \rho^2\right)^{1/2}. \quad (1)$$

$\sigma_h$ and $\sigma_v$ are the standard deviations of horizontal and vertical eye movements, $\rho$ is the Pearson product–moment correlation coefficient of fixation positions in the horizontal and vertical meridian, $k$ is dependent on the chosen probability area:

$$P = 1 - e^{-k} \quad (2)$$

And $e$ is the base of the natural logarithm. $P$ is the chosen probability for the SD that the BCEA is based on and the equation is solved for $k$.

$$k = -\ln(1 - P) \quad (3)$$

Statistical Analyses

By definition, only this constant value $k$, which is based on the chosen probability area in the equation $BCEA = 2k \pi \sigma_h \sigma_v \left(1 - \rho^2\right)^{1/2}$, separates the 2SD- and 3SD-BCEA from the 1SD-BCEA. All correlation coefficients for 1SD/2SD/3SD-BCEA values with all other variables (tracked duration, percentage of points within 2° or 4°, and so on) are thus identical. Therefore, we present the correlations exclusively for the 1SD-BCEA.

The main outcome measures in this investigation were the cloud of fixation points with $x$- and $y$-coordinates for each point and the BCVA as measured with the ETDRS system.

Data Management

The central reading center was the Doheny Imaging Reading Center (DIRC) at the Doheny Eye Institute. The data coordinating and data management center (DCC) was the Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine and Johns Hopkins Bloomberg School of Public Health. REDCap databases were used to store the data.22 All Nidek MP-1 instruments and photographers were certified by the DIRC prior to enrollment.

Results

In the prospective ProgStar study, a total of 259 patients and 489 eyes were enrolled at nine centers between October 21, 2013, and January 30, 2015.28 One participating center did not perform microperimetry using the MP-1. Overall, MP-1 testing was graded in at least one eye for 235 patients. Fixation data were missing in several instances and were available from the separate fixation task in 427 eyes and for 418 eyes derived from the sensitivity test. Table 1 shows the demographic features of these patients. The median BCVA was approximately 20/125 Snellen equivalent or 42 ETDRS letters (mean ± SD, 46.3 ± 16.3; range, 20–88).
Fixation Stability in Stargardt Disease

Table 1. Patient Characteristics: Patients With at Least One MP-1 Grading

| Patient Characteristics | Patients With at Least One MP-1 Grading | Mean ± SD | Range |
|-------------------------|------------------------------------------|-----------|-------|
| Person level, N = 235   | Age, y                                    | 33.7 ± 15.2 | 7 to 69 |
|                         | Age of onset, y                           | 20.9 ± 13.9 | 2 to 64 |
|                         | Disease duration, y                       | 12.7 ± 10.4 | 0 to 61 |
|                         | Count female (%)                         | 130 (55.3) |
|                         | Race (%)                                  |            |       |
|                         | Asian/South Asian                         | 9 (3.8)    |
|                         | African American                          | 19 (8.1)   |
|                         | White                                     | 202 (86)   |
|                         | Other                                     | 1 (0.4)    |
|                         | Unknown ethnicity                         | 4 (1.7)    |
|                         | Eye level, N = 440                        |            |       |
|                         | Best-corrected visual acuity, ETDRS letters | 46.3 ± 16.3 | 20 to 88 |

Overall Summary

The mean area of the BCEA encompassing 1 SD (68.3%) of all fixation events was 4.6 deg² when measured during the fixation test and significantly larger (12.5 deg²) when measured during the macular sensitivity test, indicating more stable fixation during the fixation test (P < 0.0001, Table 2). This is also reflected by the lower percentages of points within the 2° and 4° circles during the sensitivity test compared with the fixation test (P < 0.0001, Table 2). Using the 2SD- or the 3SD-BCEA, which are distinct from the 1SD-BCEA only through a constant factor, led to proportionately larger areas but identical proportional differences between the fixation test and the sensitivity test. The tracked test duration was aimed at approximately 30 seconds and therefore has a low SD of 5.3 seconds. The percentage of examination time tracked by the Nidek MP-1 was significantly larger during the fixation test when compared to the sensitivity test.

Table 2. Summary Fixation Stability All Eyes

| Fixation Stability | Fixation Test, N = 427 | Sensitivity Test, N = 418 |
|-------------------|------------------------|--------------------------|
|                   | Mean ± SD (Range)       | Mean ± SD (Range)         | Estimate | 95% Confidence Interval | P Value |
| 1SD-BCEA, deg²    | 4.6 ± 9.0 (0.01–134.9) | 12.5 ± 15.7 (0.04–163.9) | -8.1     | -9.9, -6.4              | <0.0001 |
| 2SD-BCEA, deg²    | 12.5 ± 24.4 (0.03–365.6) | 33.8 ± 42.6 (0.10–444.1) | -22.0    | -26.7, -17.4            | <0.0001 |
| 3SD-BCEA, deg²    | 24.0 ± 46.7 (0.06–699.9) | 64.7 ± 81.6 (0.19–850.1) | -42.2    | -51.1, -33.2            | <0.0001 |
| Percentage within 2° | 71% ± 28% (0%–100%)     | 48% ± 27% (0%–100%)      | 0.24     | 0.21, 0.26              | <0.0001 |
| Percentage within 4° | 91% ± 16% (0%–100%)     | 77% ± 21% (0%–100%)      | 0.14     | 0.12, 0.17              | <0.0001 |

Duration of Test

| Fixation Test, N = 427 | Sensitivity Test, N = 418 |
|------------------------|---------------------------|
| Mean ± SD (Range)       | Mean ± SD (Range)         | Estimate | 95% Confidence Interval | P Value |
| Total duration, s       | 36.2 ± 12.2 (20–142)      | 974.1 ± 293.9 (278–2441) | -941.1 | -974.5, -907.7          | <0.0001 |
| Duration tracked, s     | 31.3 ± 5.5 (11–75)        | 751.5 ± 152.8 (237–1244) | -720.1 | -739.2, -701.0          | <0.0001 |
| Percentage tracked, s   | 90% ± 14% (14%–100%)      | 81% ± 16% (24%–100%)     | 0.093   | 0.076, 0.11             | <0.0001 |

Fujii Classification and the BCEA

All eyes were categorized in the corresponding Fujii category (“stable,” “relatively unstable,” or “unstable”) based on the 2° and 4° circles (Table 5). Eyes in the “stable” category had the smallest 1SD-BCEAs with a mean area of 1.3 ± 1.4 deg² during the fixation test. The 1SD-BCEAs in the “relatively unstable” group (5.6 ± 4.4 deg²) and in the “unstable” group (18.5 ± 20.6 deg²) were larger. However, there was a significant amount of overlap, which is visualized by the box plots in Figure 3. For example, during the fixation test, an eye with a BCEA of 4 deg² may fall into any of the three Fujii categories.

Fixation Stability and Visual Acuity

A single linear model best described the relationship of the BCVA with fixation stability during both the fixation and sensitivity test. An increase of 1 deg² in BCEA during the fixation test was associated with a 0.15-letter (ETDRS) worse BCVA (95% confidence interval [CI], −0.33 to −0.026; P =
TABLE 3. Pearson Correlation Coefficient and P Values of the Correlation of Fixation Stability Parameters From the Separate Fixation Test With Other Fixation Parameters

| Parameters From the Fixation Test | Data From Fixation Task, Effective Sample Size 228 | Data From Macular Sensitivity Test, Effective Sample Size 215 |
|----------------------------------|-----------------------------------------------|------------------------------------------------------------|
|                                  | Percentage Within 2° | Percentage Within 4° | Percentage of Time Tracked | Total Duration | Duration Tracked | 1SD-BCEA | Percentage Within 2° | Percentage Within 4° |
|-----------------------------------|----------------------|----------------------|-----------------------------|---------------|------------------|---------|----------------------|----------------------|
| ISD-BCEA                          | −0.57                | −0.80                | −0.25                       | 0.13          | −0.09            | 0.34    | −0.31                | −0.35                |
| Percentage within 2°              | <0.0001              | <0.0001              | 0.0001                      | 0.0547        | 0.1743           | <0.0001 | <0.0001              | <0.0001              |
| Percentage within 4°              | 1.000                | 0.80                 | 0.31                        | −0.11         | 0.15             | −0.45   | 0.55                 | 0.52                 |
| Percentage within 4°              | <0.0001              | <0.0001              | 0.0959                      | 0.0250        |                  | <0.0001 | <0.0001              | <0.0001              |
|                                   | 0.80                 | 1.000                | 0.34                        | −0.14         | 0.15             | −0.45   | 0.41                 | 0.48                 |
|                                   | <0.0001              | <0.0001              | 0.0291                      | 0.0259        |                  | <0.0001 | <0.0001              | <0.0001              |

DISCUSSION

Fixation in STGD1 Using Different Metrics and Different Modes of Acquisition

We tested fixation stability, a relatively novel visual function biomarker, in a large cohort of patients with genetically confirmed STGD1 using the Nidek MP-1 both during a dedicated fixation test and during a macular sensitivity exam. Our group recently demonstrated the clinical relevance and the correlation of fixation stability with disease duration, age of onset, and visual acuity in Stargardt disease (Schönbach EM, IOVS 2016;57:ARVO E-Abstract 2694).11 We were also able to demonstrate that fixation parameters are able to detect longitudinal changes of visual function in selected cases where micronerometric sensitivity parameters failed to provide significant changes (Schönbach EM, IOVS 2017;58:ARVO E-Abstract 4635). Possibly, these fixation parameters may serve as secondary outcome measures in future clinical trials.11 It remains unclear whether the most appropriate way to measure fixation stability is during the macular sensitivity test, which is primarily conducted to test macular light sensitivity, or if a separate fixation test is necessary.

By definition, fixation is more stable when the fixation events recorded by the eye-tracking device are spatially closer together. There are different approaches to describe fixation stability. The BCEA describes the smallest elliptical area that encompasses one, two, or three SDs of all fixation events while accounting for their horizontal and vertical spread. In the presented dataset, we measured a mean 1SD-BCEA of 4.6 deg² during the fixation test. This is in line with previous articles that reported a mean fixation stability of 2.4 deg² in 60 eyes of patients with STGD1.50 We report a mean BCEA of 12.5 deg² during the sensitivity test, substantially larger than during the fixation test. We are unaware of any previously published data on fixation stability measurements in STGD1 or any other macular disease during an eye exam primarily intended to determine macular light sensitivity.

Many research groups describe fixation stability by counting the points within 2° or 4° from the gravitational center.31,32 Using the MP-1 microperimeter and a separate fixation exam, one report on 15 patients with STGD1 found less stable fixation (mean within 2°, 53%; mean within 4°, 69%)30 than our report, which may be due to the older patient age and supposedly more advanced disease in their patient cohort.
Correlation Among the Different Metrics to Describe Fixation Stability

The 2/4 degree method and the BCEA are two different metrics to quantify the spatial proximity of fixation points within the cloud of recorded fixation events. Only the BCEA considers the elliptical distribution of the fixation points. Especially eyes with macular disease\textsuperscript{33} and amblyopic eyes\textsuperscript{34} have been shown to present with a more elliptical distribution than normal eyes. In addition, the BCEA can become infinitely small and allows an accurate quantification of fixation stability in the stable end of the spectrum, while the 2/4 degree method is limited by a ceiling effect. Fixation stability outcomes from both methods have been correlated with demographic features\textsuperscript{11,32} BCVA\textsuperscript{,11,30} and fixation location,\textsuperscript{11,32} but only limited data are available on their correlation with each other. In a small group of eyes with age-related macular degeneration (AMD) undergoing a fixation test, Crossland et al.\textsuperscript{35} were able to demonstrate a weak linear correlation between the logBCEA and the 2/4 degree method. Our results on a cohort of STGD1 patients are consistent with the article by Crossland et al.\textsuperscript{35}

**Figure 1.** Fixation was tested during a separate fixation task (A) where the patient was instructed to focus on the center of a red cross. Blue dots represent the recorded fixation events. Afterward, fixation was determined during a sensitivity exam (B). Here, a higher number of fixation points is available as a result of the longer test duration. Fixation events also seem to be more widely scattered during the sensitivity exam.

**Figure 2.** Correlation of the bivariate contour ellipse area with the percentage of fixation points within 2° (A, B) and 4° (C, D) during a separate fixation test (A, C) and the macular sensitivity test (B, D).
We compared fixation data from the fixation test and the sensitivity test and found significantly more stable fixation during the fixation exam. This result is not surprising because the patients are given different instructions in the two tests. During the short fixation exam, the patient makes an effort to look at the center of the fixation target as steadily as possible, whereas he or she focuses on not missing any displayed light stimuli during the sensitivity test. Furthermore, longer test duration has been shown to adversely affect the stability of fixation, possibly due to effects of fatigue. Another explanation is that if patients just keep their eye in one position during the short fixation task, they will be assessed as having stable fixation when they may in fact be attending to something else.

The design of this research introduces an important limitation to the interpretation of our correlations with test duration because the fixation test was aimed at 30 seconds and the sensitivity test was conducted until a threshold for all 68 retinal test locations was determined. However, we were able to find a correlation between fixation stability and the proportion of tracked to total test duration. We expected an association because the retina of unstable eyes is often harder to follow. We found a weak yet important association of the percentage of tracked time with fixation stability (Tables 3, 4).

The Fujii classification is a straightforward categorization of fixation stability results and has been extensively discussed in the literature. We add that there is a significant range of overlap between its different categories. Our analysis shows that a single BCEA value from the fixation test between 3.8 and 8.5 deg² can correspond to each of the three Fujii categories, making the Fujii classification less useful. A similar range of overlap could also be found for the sensitivity test (4.4–9.8 deg²). Other disadvantages of this classification include that counting the fixation points within 28 or 48 from the center of gravity does not recognize the presence of two spatially distinct but stable PRLs (preferred retinal locus), which is common in macular diseases. In other words, this method will categorize both eyes with truly poor fixation as well as those with multiple distinct PRLs as unstable, whereas the BCEA has been reported for use in eyes with multiple PRLs. Moreover, the Fujii classification categorizes vastly different degrees of stability in the same group. Both 100% and 75% of points within 28 are considered “stable,” discarding much useful information. We showed in a previous analysis that small deteriorations of fixation stability are associated with a large effect on visual acuity. We therefore speculate that this is the reason why studies in AMD showed that the fixation report generated by the MP-1 is very poorly correlated to any parameters of reading. The BCEA is a less quantized measure of fixation and better correlated to reading speed. Additionally, functional analyses have shown that the BCEA is more...
BCVA scores, regardless of whether the results are derived

BCEAs seem to be associated with a large range of different

applicable in clinical practice. Our results show that small

present visual acuity as an outcome of the stability of fixation.

we showed that an earlier onset of STGD1 is associated with

more unstable fixation and that the association with BCVA is

closely linked to reading speed than the central 2/4 degree

method.40

Association With Visual Acuity

BCVA and fixation stability correlate, and significant associations have been demonstrated in STGD1,11 AMD,37 and infantile nystagmus.41 In a previous article using fixation tests, we showed that an earlier onset of STGD1 is associated with more unstable fixation and that the association with BCVA is most pronounced when fixation is relatively central.11 Also when measured during the sensitivity test, we found significant associations of BCVA with fixation stability (Schönbach EM, IOVS 2016;57:ARVO E-Abstract 2694). However, we are unaware of any previous study comparing stability values from both the fixation test and the sensitivity test. We decided to present visual acuity as an outcome of the stability of fixation. The opposite direction also seems plausible but appears less applicable in clinical practice. Our results show that small BCEAs seem to be associated with a large range of different BCVA scores, regardless of whether the results are derived

from a dedicated fixation exam or from the sensitivity test. Stable fixation (BCEA ≤ 50 deg²), regardless of its origin from a fixation test or sensitivity test, is almost universally associated with a good BCVA score (BCVA > 60 ETDRS letters), whereas less stable fixation tends to more often be associated with poor BCVA. Our results suggest that fixation data derived from either the fixation or the sensitivity test can reasonably describe the fixation aspect of vision and both tests correlate with BCVA. However, only the association of fixation stability from the sensitivity test was significantly associated with BCVA. One possible explanation is that patients may be able to keep their eyes straight during the short fixation task with a marked underestimation of the BCEA. The higher percentage of tracked test duration during the fixation test supports this theory. From this perspective, the fixation data from the sensitivity test seem more useful, and the continuous measures more than the categorical measures. Fixation data from the sensitivity test may be more unstable, but they give a rough idea of what the outcome of the fixation test will be. Since many similarities exist between STGD1 and other macular diseases, the presented principles may also apply to, for example, AMD.

Table 6. Summary of 1SD–BCEA, Percentage of Fixation Points Within 2 and 4 Degrees by Visual Acuity Level

| Applied Measure and Visual Acuity Group | Data From Fixation Test | Data From Sensitivity Test |
|----------------------------------------|-------------------------|---------------------------|
| N                                      | Mean ± SD (Deg²)        | (Range) (Deg²)            | N                                      | Mean ± SD (Deg²) | (Range) (Deg²) | Estimate | 95% CI | P Value |
| 1–SD BCE                               |                         |                          |                                         |                         |                          |          |       |        |
| BCVA ≥ 20/25                           | 17 0.33 ± 0.28 (0.04 to 1.22) |                          | 14 4.16 ± 4.98 (0.17 to 15.94) | –3.2 (–5.5, –0.80) | 0.0087                  |
| BCVA 20/25 – 20/70                      | 75 2.3 ± 5.3 (0.06 to 36.19)  |                          | 72 9.16 ± 22.12 (0.16 to 163.85) | –6.9 (–11.6, –2.20) | 0.004                   |
| BCVA 20/70 – 20/200                     | 234 4.17 ± 5.48 (0.01 to 36.2) |                          | 230 12.06 ± 13.97 (0.25 to 103.95) | –8.4 (–10.6, –6.16) | <.0001                  |
| BCVA worse than 20/200                  | 101 8.12 ± 15.32 (0.49 to 134.89) |                          | 102 16.84 ± 15.96 (0.04 to 45)  | –9.9 (–13.4, –6.41) | <.0001                  |
| Percentage of points within 2 deg      | 17 99% ± 2% (94% to 100%)  |                          | 14 78% ± 28% (13% to 100%)   | 0.18 (0.04, 0.31)   | 0.0125                  |
| BCVA 20/25 – 20/70                      | 75 87% ± 25% (9% to 100%)  |                          | 72 73% ± 29% (10% to 100%)   | 0.13 (0.07, 0.19)   | <.0001                  |
| BCVA 20/70 – 20/200                     | 234 71% ± 27% (0% to 100%) |                          | 230 45% ± 23% (0% to 100%)   | 0.26 (0.23, 0.30)   | <.0001                  |
| BCVA worse than 20/200                  | 101 57% ± 27% (0% to 98%)  |                          | 102 32% ± 19% (4% to 81%)   | 0.25 (0.20, 0.30)   | <.0001                  |
| Percentage of points within 4 deg      | 17 100% ± 0% (99% to 100%) |                          | 14 92% ± 16% (43% to 100%)  | 0.071 (0.004, 0.14) | 0.0488                  |
| BCVA 20/25 – 20/70                      | 75 95% ± 13% (32% to 100%) |                          | 72 88% ± 17% (34% to 100%)  | 0.071 (0.036, 0.11) | <.0001                  |
| BCVA 20/70 – 20/200                     | 234 92% ± 14% (10% to 100%) |                          | 230 77% ± 20% (3% to 100%)  | 0.15 (0.13, 0.18)   | <.0001                  |
| BCVA worse than 20/200                  | 101 85% ± 21% (0% to 100%) |                          | 102 68% ± 21% (13% to 99%)  | 0.19 (0.15, 0.24)   | <.0001                  |
Fixation Stability in Stargardt Disease

Limitations

As mentioned earlier, important differences between the fixation test and the full microperimetry exam introduce limitations to this research. Patients pay attention to different aspects in both tests (fixating only the red cross versus fixating the red cross and focusing on displayed light stimuli at the same time). The analysis also assumes that fixation is not wandering and that a very high number of fixation events is comparable to a much lower number. Not surprisingly, the tests do not correlate very well, and stable fixation during a short test does not necessarily predict stable fixation during a light detection task. However, in light of the paucity of literature on this subject, the primary purpose of this article was to provide a comparison between the two tests and the different measures for the clinician, although there are limitations, from a physiological standpoint for the mentioned reasons.

Conclusions

Our results demonstrate that the continuous BCEA has certain advantages over both the 2/4 degree method and the Fujinami classification. The latter two seem of little use when fixation is in a certain range. The BCEA from both the separate fixation and the sensitivity exam are functional biomarkers that correlate with each other and with BCVA. But only the data from the sensitivity exam showed a statistically significant association with BCVA. Data from both exams seem to describe the fixation dimension of vision reasonably well. BCEA values from the sensitivity test are larger, and one explanation is that a patient can keep his or her eye in one position during the short fixation task and will be assessed as having stable fixation when in fact he or she is attending to something else. We conclude that the separate fixation exam may be redundant when fixation is also tested during the sensitivity exam. Further steps to validate these biomarkers include investigation of their usefulness to monitor disease progression in longitudinal studies and to test if changes of fixation stability correlate with other outcome parameters.

Acknowledgments

Supported by the Foundation Fighting Blindness Clinical Research Institute (FFB CRI, The ProgStar studies) and a grant to FFB CRI by the U.S. Department of Defense U.S. Army Medical Research and Material Command: The Telemedicine and Advanced Technology Research Center; Fort Meade, Maryland, United States (Grants W81-XWH-071-0720 and W81XWH-092-0189); The Shulsky Foundation, New York, New York, United States; Ocular Albinism Research Fund (Clark Enterprises, Inc.); unrestricted grant to the Wilmer Eye Institute from Research to Prevent Blindness; Baylor-Johns Hopkins Center for Mendelian Genetics (National Human Genome Research Institute, NHGRI/NIH); the Leopoldina Fellowship Program, German National Academy of Sciences (Halle, Germany; Grant LPDS 2015-14) (EMS); the Austrian Science Fund (FWF; Project no. J 3385-B23) (RWS). The authors alone are responsible for the content and writing of this paper.

Disclosure: E.M. Schönbach, German National Academy of Sciences Leopoldina (F); M.A. Ibrahim, None; X. Kong, None; R.W. Strauss, None; B. Muñoz, None; D.G. Birch, None; J.S. Sunness, None; S.K. West, Alcon Research Institute (S); Research to Prevent Blindness (S); H.P.N. Scholl, Acucela, Inc. (F); QLT, Inc. (F); NightstaRx, Ltd. (F); Astellas Institute for Regenerative Medicine (C); Boehringer Ingelheim Pharma GmbH & Co. KG (C); Coleman Research Group, Inc. (C); Daiichi Sankyo (C); DeMatteo Monness Consulting (C); Gerson Lehrman Group (C); Guidepoint Global, LLC (C); Intellia Therapeutics, Inc. (C); Ocata Therapeutics, Inc. (C); Shire (C); F Hoffmann-La Roche; Ltd. (R, S), Genentech, Inc. (R, S), Genzyme, Corp. (R, S), Ora, Inc. (R, S), ReNeuron Group, Plc. (R, S), Sanofi (R, S), Clinical Advisory Board of Gensight Biologics (S), Food and Drug Administration (S), Ophthalmic Devices Panel of the Medical Devices Advisory Committee (S), Scientific Advisory Board of Vision Medicines, Inc. (S)

References

1. Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular dystrophy. *Opthalmic Genet*. 2009;30:63–68.
2. van Huet RA, Bax NM, Westeneng-van Haafsten SC, et al. Fixation stability in Stargardt disease. *Invest Ophtalmol Vis Sci*. 2014;55:7467–7478.
3. Nakao T, Tsujikawa M, Sawa M, Gomi F, Nishida K. Fixation instability in patients with Japanese Stargardt’s disease and good visual acuity. *Jpn J Ophtalmol*. 2012;56:584–588.
4. Westeneng-van Haafsten SC, Boon CJ, Cremer FP, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt’s disease. *Optical Biology*: 2012;119:1199–1210.
5. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models, and therapeutic options. *Br J Ophtalmol*. 2017;101:25–30.
6. Feucht N, Schonbach EM, Lanzl I, Kotljar K, Lohmann CP, Maier M. Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. *Clin Ophtalmol*. 2013;7:173–178.
7. Fishman GA, Faber ME, Patel BS, Derlacki DJ. Visual acuity loss in patients with Stargardt’s macular dystrophy. *Ophtalmology*: 1987;94:809–814.
8. Kong X, Strauss RW, Michaelides M, et al. Visual acuity loss and associated risk factors in the retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2). *Ophtalmology*: 2016;123:1887–1897.
9. Rigoni E, Cacciotti V, Trabucco P. Normal values and repeatability of bivariate contour ellipse area (BCEA) in microperimetry MP-1. *Low Vision J*. 2014;1:1.1
10. Bellmann C, Feely M, Crossland MB, Kanaanou SA, Rubin GS. Fixation stability using central and pericentral fixation targets in patients with age-related macular degeneration. *Ophtalmology*: 2004;111:2265–2270.
11. Schönbach EM, Ibrahim MA, Strauss RW, et al. Fixation location and stability using the MP1 microperimeter in Stargardt disease: ProgStar Report No. 3. *Ophtalmol Retina*. 2016;1:68–76.
12. Crossland MB, Cullum LE, Rubin GS. Fixation stability and reading speed in patients with newly developed macular disease. *Opthalmic Physiol Opt*. 2004;24:327–353.
13. Sunness JS, Applegate CA, Haselwood D, Rubin GS. Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. *Ophtalmology*: 1996;103:1458–1466.
14. Nilsson UL, Frennesson C, Nilsson SE. Location and stability of a newly established eccentric retinal locus suitable for reading, achieved through training of patients with a dense central scotoma. *Optom Vis Sci*. 1998;75:873–878.
15. Nilsson UL, Frennesson C, Nilsson SE. Patients with AMD and a large absolute central scotoma can be trained successfully to use eccentric viewing, as demonstrated in a scanning laser ophthalmoscopy. *Vision Res*. 2003;43:1777–1787.
16. Tarita-Nistor L, Gonzalez EG, Markowitz SN, Steinbach MJ. Plasticity of fixation in patients with central vision loss. *Vis Neurosci*. 2009;26:487–494.
17. Tarita-Nistor L, Gonzalez EG, Markowitz SN, Steinbach MJ. Fixation characteristics of patients with macular degeneration.
Fixation Stability in Stargardt Disease

18. Macedo AF, Crossland MD, Rubin GS. Investigating unstable fixation in patients with macular disease. Invest Ophthalmol Vis Sci. 2011;52:1275–1280.

19. Plank T, Frolo J, Brandl-Ruhle S, et al. Gray matter alterations in visual cortex of patients with loss of central vision due to hereditary retinal dystrophies. Neuroimage. 2011;56:1556–1565.

20. Liu H, Bittencourt MG, Sophie R, et al. Fixation stability measurement using two types of microperimetry devices. Trans Vis Sci Tech. 2015;4(2):3.

21. Tarita-Nistor L, Gonzalez EG, Mandelcorn MS, Lillakas L, Steinbach MJ. Fixation stability, fixation location, and visual acuity after successful macular hole surgery. Invest Ophthalmol Vis Sci. 2009;50:84–89.

22. Scholl HP, Strauss RW, Singh MS, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8:368rv6.

23. Scholl HP, Sahel JA. Gene therapy arrives at the macula. Lancet. 2014;383:1105–1107.

24. Schonbach EM, Scholl HP. Fundus autofluorescence in a subclinical case of Best disease. Retinal Cases Brief Rep. 2016;11:5159–5162.

25. Kong X, West SK, Strauss RW, et al. Progression of visual acuity and fundus autofluorescence in recent-onset Stargardt disease: ProgStar Study Report #4 [published online ahead of print April 28, 2017]. Ophthal Retina. doi:10.1016/j.oret.2017.02.008.

26. Schonbach EM, Wolfson Y, Strauss RW, et al. Macular sensitivity measured with microperimetry in Stargardt disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7. JAMA Ophthalmol. 2017;135:696–705.

27. Schonbach EM, Chaikitmongkol V, Annam R, et al. 7-Hexagon multifocal electroretinography for an objective functional assessment of the macula in 14 seconds. Ophtalmic Res. 2017;58:117–124.

28. Strauss RW, Ho A, Munoz B, et al. The natural history of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: design and baseline characteristics: ProgStar Report No. 1. Ophthalmaiology. 2016;126:817–828.

29. Fujiy GY, de Juan E Jr, Sunness J, Humayun MS, Pieramici DJ, Chang TS. Patient selection for macular transection surgery using the scanning laser ophthalmoscope. Ophthalmaiology. 2002;109:1737–1744.

30. Reinhard J, Messias A, Dietz K, et al. Quantifying fixation in patients with Stargardt disease. Vision Res. 2007;47:2076–2085.

31. Plank T, Frolo J, Farzana F, Brandl-Ruhle S, Renner AB, Greenlee MW. Neural correlates of visual search in patients with hereditary retinal dystrophies. Hum Brain Mapp. 2013;34:2607–2623.

32. Testa F, Melillo P, Di Iorio V, et al. Macular function and morphologic features in juvenile Stargardt disease: longitudinal study. Ophthalmaiology. 2014;121:2399–2405.

33. Kabanarou SA, Crossland MD, Bellmann C, Rees A, Culham LE, Rubin GS. Gaze changes with binocular versus monocular viewing in age-related macular degeneration. Ophthalmaiology. 2006;113:2251–2258.

34. Subramanian V, Jost RM, Birch EE. A quantitative study of fixation stability in amblyopia. Invest Ophthalmol Vis Sci. 2013;54:1998–2003.

35. Crossland MD, Culham LE, Kabanarou SA, Rubin GS. Preferred retinal locus development in patients with macular disease. Ophthalmaiology. 2005;112:1579–1585.

36. Longhin E, Convento E, Pilotto E, et al. Static and dynamic retinal fixation stability in microperimetry. Can J Ophthalmol. 2013;48:375–380.

37. Whittaker SG, Budd J, Cummings RW. Eccentric fixation with macular scotoma. Invest Ophthalmol Vis Sci. 1988;29:268–278.

38. Deruaz A, Whatham AR, Mermoud C, Safran AB. Reading with multiple preferred retinal loci: implications for training a more efficient reading strategy. Vision Res. 2002;42:2947–2957.

39. Lei H, Schuchard RA. Using two preferred retinal loci for different lighting conditions in patients with central scotomas. Invest Ophthalmol Vis Sci. 1997;38:1812–1818.

40. Crossland MD, Dunbar HM, Rubin GS. Fixation stability measurement using the MP1 microperimeter. Retina. 2009;29:651–656.

41. Dell’Osso LF, Leigh RJ, Sheth NV, Daroff RB. Two types of foveation strategy in “latent” nystagmus: fixation, visual acuity and stability. Neuroophthalmaiology. 1995;15:167–186.

42. Behrend C, Schonbach E, Coombs A, Coyne E, Prasarn M, Rechtine G. Smoking cessation related to improved patient-reported pain scores following spinal care in geriatric patients. Geriatr Orthop Surg Rehabil. 2014;5:191–194.

43. Behrend CJ, Schonbach EM, Vaccaro AR, Coyne E, Prasarn ML, Rechtine GR. Maximum pain on visual analog scales in spinal disorders. Spine J. 2016;17:1061–1065.